PRESS

Industry Programs

HomeProgram ▶ Industry Programs

Enhance your educational experience during ATS 2021 by listening to industry experts discuss the latest information on products/services or disease awareness related to pulmonary, critical care, and sleep medicine.

Select programs are available on-demand through the end of the virtual conference, July 2. To access the industry program, click on the title of the program below to be directed to the ATS 2021 virtual platform. The platform is only accessible by registered attendees.


Available On-Demand


A Breath of Fresh Air in Pediatric Asthma


This non-CME educational program is sponsored by Integritas Communications and is supported by an independent educational grant from Regeneron Pharmaceuticals and Sanofi Genzyme.
Open to all attendees
Topic: Asthma

During this 1-hour Engaging the Patient™ program, two asthma specialists will review the consequences and disparities of severe asthma within the pediatric population and share their interpretive insights on its characteristics and underlying pathophysiology as well as the rationale for targeted biologic therapies. Additionally, the latest clinical trial evidence for the use of newer biologic therapies within this pediatric population will be presented along with their positioning within recent published guidelines. Interactive faculty discussions surrounding the management of young patients with severe asthma as well as key elements for shared decision making will support the translation of this information to practice. Lastly, an intimate view of the parents’ perspective will be provided via prerecorded video, highlighting the immense burden of disease and the impact asthma has on patients and their families. Following participation, attendees will be motivated and better prepared to implement timely and effective treatment plans for the management of their young patients with severe asthma.

Speakers:

  • Mario Castro, MD, MPH, Chief, Pulmonary, Critical Care and Sleep Medicine; Vice Chair for Clinical and Translational Research; Director, Frontiers: University of Kansas Clinical and Translational Science Institute; Director, Rainbow Clinical Trials Science Unit, University of Kansas Medical Center
  • Wanda Phipatanakul, MD, MS, Professor of Pediatrics; Director, Clinical Research Center, Harvard Medical School; Boston Children's Hospital



An Animated Exploration of Chronic Fibrosing Interstitial Lung Disease: From Diagnosis to Management in the Era of Antifibrotic Therapy


This non-CME educational program is sponsored by PVI, PeerView Institute for Medical Education and supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Open to all attendees
Topic: ILD

Pulmonology experts will discuss the latest clinical efficacy and safety data for novel and emerging therapies for CF-ILD. The discussion will be supplemented with animated video and infographics.

Speakers:

  • Kevin R. Flaherty, MD, MS, Professor of Medicine, Co-Director, Interstitial Lung Disease Destination Clinic, University of Michigan
  • Erica L. Herzog, MD, PhD, Professor of Medicine and Pathology, Associate Dean, Medical Student Research, Yale School of Medicine
  • Lisa H. Lancaster, MD, Professor of Medicine, Director, Interstitial Lung Disease Program, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center



Current Trends in High-Flow Therapy (HFT)


Sponsored by Philips
Open to all attendees
Topic: High Flow Oxygen Therapy

The latest trends for using high-flow therapy in respiratory support.

Speaker:

  • Thomas Piraino, RRT, FCSRT, FAARC, Registered Respiratory Therapist, Kingston General Hospital



Exploring Type 2 Inflammation in Nasal Polyps and Beyond


Sponsored by Novartis Pharmaceuticals Corporation
Open to U.S. attendees only
Topic: Airway Comorbidities

A disease state overview of nasal polyps and type 2 inflammation

Speaker:

  • Monica Kraft, MD, The Robert and Irene Flinn Endowed Chair in Medicine, The University of Arizona College of Medicine



Exposing a Hidden Majority in COPD: Real-World Insights on Outcomes and Dual Bronchodilation


Sponsored by Boehringer Ingelheim
Open to all attendees
Topic: COPD

During this event, our experts will review:

  • How has the pandemic posed challenges for COPD management and in what ways have clinicians adapted?
  • Are the appropriate patients getting dual bronchodilation and how can patient phenotypes inform inhaler choice?
  • What can real-world evidence tell us about health outcomes with dual bronchodilation and how does compliance with GOLD treatment guidelines impact health outcomes?

Speakers:

  • Nicola Hanania, MD, MS, Associate Professor of Medicine in the Section of Pulmonary and Critical Care Medicine and Director of the Asthma and COPD Clinical Research Center, Baylor College of Medicine
  • Sanjay Sethi, MD, Professor of Medicine, Chief of the Pulmonary/Critical Care/Sleep Medicine Division, Assistant Vice President for Health Services, Director of the Clinical Research Office and Deputy Director of the UB Clinical and Translational Science Institute, University of Buffalo, SUNY



Identifying Autoimmune Interstitial Lung Diseases: A Rheumatologist’s Perspective


Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Open to all attendees
Topic: ILD

Join expert rheumatologist Dr. Richard Silver as he discusses identifying autoimmune interstitial lung diseases, reviews patient case studies, and discusses the importance of early disease recognition. This presentation is sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.

Speakers:

  • Richard Silver, MD, Professor of Medicine and Pediatrics, Vice Chair, Development, Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC



Improving Prognosis in SSc-ILD: Best Practices in Diagnosis, Optimizing Clinical Management, and Efficient Patient Communication


This non-CME educational program is sponsored by Physician's Educational Resource and supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Open to all attendees
Topic: SSc-ILD

Interstitial lung disease (ILD) is a frequent and debilitating complication of systemic sclerosis (SSc) with a complex pathophysiology. Up to 90% of the 50,000 individuals in the United States diagnosed with SSc will develop some degree of ILD, determining both disease severity and prognosis. SSc-ILD is characterized by systemic inflammation, progressive scarring of the lungs, and eventual respiratory failure. Until recently, there were no approved therapies but now patients with SSc-ILD may benefit from early intervention to prevent disease progression.

A panel of experts will first review the classification and pathophysiology of SSc-ILD and then share insights for initial pulmonary assessment. Patient cases will be used to identify predictors of disease progression and considerations for initiation of therapy with best approaches for shared decision-making in discussing patient expectations.

Speakers:

  • Steven D. Nathan, MD, Medical Director, Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital
  • Kristin B. Highland, MD, MSCR, Director, Rheumatic Lung Disease Program, Cleveland Clinic
  • Justin Oldham, MD MS, Associate Professor of Medicine
    Autoimmune Lung Center and Interstitial Lung Disease Program, University of California at Davis
  • Joshua Solomon, MD, Associate Professor of Medicine, National Jewish Health



Interactive Exchange™ – Swimming Upstream in Severe Asthma: New Pathways to Patient Management


This non-CME educational program is jointly sponsored by Integritas Communications and Global Education Group and is supported by an independent educational grant from AstraZeneca.
Open to all attendees
Topic: Asthma

This virtual live Interactive Exchange™ severe asthma program will provide a blended educational format that promotes opportunities for various interactions and dialogue among presenting faculty and participants. The program will begin with an introductory video animation that imparts foundational information─including key upstream inflammatory pathways, the role of the epithelium in asthma development, mechanisms underlying common phenotypes, and the rationale for targeted biologic therapies─for the program’s interactive discussions. Expert faculty will focus on key topics, such as recent clinical trial evidence for emerging pharmacotherapies that target type 2 (T2)–low disease, potential changes to evidence-based treatment algorithms, and strategies for effectively communicating biologic treatment options with patients. This multimedia experience will deliver optimized participant engagement while ensuring the sharing of experiences surrounding challenging clinical topics in today’s severe asthma landscape.

Speakers:

  • Reynold A. Panettieri, Jr., MD, Professor of Medicine, Robert Wood Johnson Medical School Vice Chancellor, Clinical & Translational Science Director, Rutgers Institute for Translational Medicine & Science Emeritus Professor of Medicine, University of Pennsylvania, Child Health Institute of New Jersey
    Rutgers, The State University of New Jersey
  • Jonathan Corren, MD, Associate Clinical Professor of Medicine and Pediatrics Medical Director, Jonathan Corren M.D. and Associates, David Geffen School of Medicine, University of California, Los Angeles
  • Monica Kraft, MD, Professor, Medicine Chair, Department of Medicine The Robert and Irene Flinn Endowed Chair in Medicine Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center, University of Arizona (UA) College of Medicine – Tucson



IPF Disease Challenge


This non-CME educational program is sponsored by the France Foundation and supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Open to all attendees
Topic: IPF

Are you up for the IPF Disease Challenge? Game on!
Unwind after a long day with a Kahoot!

This is NOT an old-school didactic lecture! Discover better ways to manage your patients with IPF while engaging in some “friendly competition.” Gaming elements will answer questions such as:

  • How do I integrate new IPF treatment info into practice?
  • When and why would I start antifibrotic therapy?
  • Should I stop or switch treatment?
  • How do I emphasize to patients that treatment adherence impacts disease progression?

Hosted by Kevin Flaherty, MD, from the University of Michigan and Lisa H. Lancaster, MD, from Vanderbilt University.

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Speakers:

  • Lisa H. Lancaster, MD, Medical Director Interstitial Lung Disease Program, Professor of Medicine, Vanderbilt University
  • Kevin Robert Flaherty, MD, Director of the Michigan Medicine Interstitial Lung Disease Program, Professor of Medicine, University of Michigan



Pandemic in practice: Impact of viral variance, hyperinflammation and vaccinations on COVID-19 outcomes


Sponsored by GlaxoSmithKline
Open to all attendees
Topic: COVID-19

This medical symposium will educate attendees on the drivers of COVID-19 in the community, and the factors that contribute to disease progression in hospital. Join us for an exploration of practice management in mild, moderate, severe and critical cases.

Dr. Robert Gottlieb will explore the impact of vaccination campaigns and viral variants on both incidence and severity of disease, while Dr. Deepa Gotur will discuss the role of GMCSF in Hyperinflammation in the Severe COVID Patient.

Speakers:

  • Deepa Bangalore Gotur, MD, Associate Professor of Clinical Medicine, Academic Institute, Weill Cornell Medical College
  • Robert Gottlieb, MD, Board Certified Transplant Cardiologist, Principal investigator of Baylor Scott and White active clinical trials for COVID-19, Baylor Scott & White Health



PRECISION: Using Evidence-based Tools to Advance the Identification and Management of Uncontrolled Asthma


Sponsored by AstraZeneca
Open to all attendees
Topic: Asthma

This program aims to help health care providers:

  • Recognize the importance of past, present, and future burden associated with uncontrolled asthma in the United States
  • Gain awareness of interventions designed to improve the diagnosis and management of uncontrolled asthma
  • Understand how the PRECISION initiative has united a network of diverse scientific and clinical leaders and local health care professionals to help address the unmet need associated with uncontrolled asthma
  • Learn about PRECISION tools designed for all clinicians to help with identifying and assessing uncontrolled asthma and accelerating the patient journey toward precision medicine in practice

Speakers:

  • Shyam Subramanian, MD, FCCP, Section Chief, Specialty Clinics, Division Chief, Pulmonary/Critical Care/Sleep, Sutter Gould Medical Foundation, Tracy, CA



Serotonin Pathobiology in Pulmonary Arterial Hypertension and Phase 2b Investigation of the Novel Therapy Rodatristat Ethyl (RE) in WHO Group 1 PAH


Sponsored by Altavant Sciences
Open to all attendees
Topic: Pulmonary Arterial Hypertension

This program will include an expert overview of the role serotonin plays in the pathogenesis of PAH, present the mode of action of rodatristat ethyl; a novel inhibitor of peripheral serotonin via targeting of tryptophan hydroxylase 1, and provide an overview of the phase 2b clinical program, ELEVATE 2

Speakers:

  • Bill Symonds, PharmD, Chief Executive Officer, Altavant Sciences
  • Marc Humbert, MD, PhD, Professor, Respiratory Medicine, Université Paris-Saclay
  • Stephen Wring, PhD, Vice President, Research and Development, Altavant Sciences
  • Howard M Lazarus, MD, Chief Medical Officer, Altavant Sciences



Targeting Eosinophils: A Potent Contributor to Severe Asthma


Sponsored by AstraZeneca
Open to all attendees
Topic: Asthma

It’s time to rethink patient goals in severe asthma. Please join us to view a pre-recorded program to learn about a targeted biologic treatment option that targets a key contributor of severe uncontrolled asthma. Listen to a national expert to explore this treatment option’s clinical efficacy, mechanism of action, safety profile data, and hypothetical patient cases.

Speakers:

  • Michael Wechsler, MD, MMSc, Pulmonologist, Director, Cohen Family Asthma Institute, Director, Asthma Program, Professor of Medicine, National Jewish Health, Denver, CO



Tips and Tricks for Bronchoscopic Lung Volume Reduction for Advanced Emphysema


Sponsored by Temple Lung Center
Open to all attendees
Topic: COPD

Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States. Despite optimal pharmacological treatment, many patients with chronic obstructive pulmonary disease remain very disabled. Bronchoscopic lung volume reduction, which involves the insertion of valves into the airways with the intension of improving operating lung volume, could be a valuable treatment option for some patients with advanced emphysema. In this program, participants will learn procedural tips and tricks regarding valve placement from internationally renowned EBV expert Gerard Criner, MD.

Speakers:

  • Gerard J. Criner, MD FACP, FACCP, Chair and Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Temple University Health System
  • Nathaniel Marchetti, DO, Professor, Thoracic Medicine and Surgery, Lewis Katz School of Medicine at Temple University, Temple University Health System



TSLP in Asthma: Examining the Evidence


Sponsored by Amgen / AstraZeneca
Open to all attendees
Topic: Asthma

There’s a new way to think about asthma and it starts at the top of the inflammatory cascade. Join us as two experts explore the role of a key epithelial cytokine, thymic stromal lymphopoietin (TSLP), in driving multiple downstream inflammatory pathways.

Speakers:

  • Mario Castro, MD, MPH, Pulmonologist Chief, Pulmonary, Critical Care and Sleep Medicine Vice Chair for Clinical and Translational Research Director, Frontiers: University of Kansas Clinical and Translational Science Institute Director, Rainbow Clinical Trials Science Unit, University of Kansas School of Medicine



Two Approaches to COPD: Focus on the lungs or look beyond?


Sponsored by AstraZeneca
Open to U.S. attendees only
Topic: COPD

To help address the ongoing burden of COPD mortality, two speakers will discuss how views on COPD are changing and if we should still approach COPD as a disease only affecting the lungs. You decide.

Speakers:

  • MeiLan Han, MD, MS, Professor of Medicine, Division of Pulmonary and Critical Care, University of Michigan
  • Fernando Martinez, MD, MS, Chief of the Pulmonary and Critical Care Medicine Division, Weill Cornell Medicine



Using the ROX index to help timing of intubation in patients supported with Nasal High Flow: Why, When and How?


Sponsored by Fisher & Paykel Healthcare
Open to all attendees
Topic: Respiratory Failure

One of the foremost concerns of HFNC use is that it may delay a needed intubation by masking the signs of disease progression. Importantly, this delay has been associated with worse patient outcomes. With the aim of trying to identify patients who will most likely to fail with HFNC and would need to be intubated, we described the use of the ROX index, defined as the ratio between SpO2/FiO2 and respiratory rate. In essence, we reported that HFNC patients with higher ROX index are less likely to require intubation. After this initial description, we validated these findings in an international multicentric study. Moreover, in this second study, we also elucidated different thresholds of the ROX index to identify higher risk for intubation among HFNC patients. In this presentation, we will 1) review the derivation, validation, and application of the ROX index; 2) describe the implementation of the ROX index; and 3) evaluate future application and research opportunities for the use of ROX index.

Speaker:

  • Oriol Roca, MD, PhD, Medical Coordinator, Intensive Care Department, Vall d'Hebron University Hospital, Barcelona, Spain



Utility of Envisia Genomic Classifier in Multi-Disciplinary ILD Management


Sponsored by Veracyte
Open to all attendees
Topic: ILD

In this multi-disciplinary (MDD) discussion, ILD experts will review a range of cases from the Envisia BRAVE sample collection study and discuss the role of the Envisia genomic classifier in the diagnosis and prognosis of ILD patients in clinical practice.

Speakers:

  • Lisa H. Lancaster, MD, Professor of Medicine Division of Allergy, Pulmonary and Critical Care Medicine, Medical Director ILD Program, Vanderbilt University Medical Center
  • David A. Lynch, MB, Professor of Radiology, National Jewish Health
  • Thomas V. Colby, MD, Emeritus Professor of Laboratory Medicine and Pathology, Mayo Clinic